tiprankstipranks
Advertisement
Advertisement

IMRX Stock Latest News

Immuneering announces updated data from Phase 2a trial for atebimetinib
The FlyImmuneering announces updated data from Phase 2a trial for atebimetinib
6d ago
IMRX
Immuneering announces presentation of new genetic data at 2026 AACR
PremiumThe Fly
Immuneering announces presentation of new genetic data at 2026 AACR
7d ago
IMRX
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
11d ago
ANGX
IMRX
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
2M ago
EVAX
IMRX
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
2M ago
MWH
AKTS
Immuneering price target lowered to $12 from $13 at Piper Sandler
PremiumThe FlyImmuneering price target lowered to $12 from $13 at Piper Sandler
2M ago
IMRX
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
Premium
Ratings
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
2M ago
IMRX
Midday Fly By: Rising oil prices, falling employment sink stocks
Premium
The Fly
Midday Fly By: Rising oil prices, falling employment sink stocks
2M ago
BA
BX
Immuneering reports Q4 EPS (18), consensus (31c)
PremiumThe Fly
Immuneering reports Q4 EPS (18), consensus (31c)
2M ago
IMRX
Immuneering sees cash runway into 2029
PremiumThe Fly
Immuneering sees cash runway into 2029
2M ago
IMRX
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
PremiumThe Fly
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
4M ago
IMRX
RVMD
Midday Fly By: Defense stocks surge on Trump budget request
PremiumThe Fly
Midday Fly By: Defense stocks surge on Trump budget request
4M ago
F
AA
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
PremiumRatingsImmuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
4M ago
IMRX
Closing Bell Movers: Defense stocks surge on Trump military budget comments
Premium
The Fly
Closing Bell Movers: Defense stocks surge on Trump military budget comments
4M ago
FC
GD
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
Premium
The Fly
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
4M ago
IMRX
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
PremiumCompany Announcements
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
4M ago
8K
IMRX
Immuneering management to meet with Oppenheimer
PremiumThe Fly
Immuneering management to meet with Oppenheimer
4M ago
IMRX
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
PremiumThe Fly
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
4M ago
IMRX
Immuneering on track to dose first patient in pancreatic cancer trial in 2026
PremiumThe Fly
Immuneering on track to dose first patient in pancreatic cancer trial in 2026
4M ago
IMRX
Immuneering to be added to the Nasdaq Biotechnology Index
PremiumThe FlyImmuneering to be added to the Nasdaq Biotechnology Index
4M ago
IMRX
Immuneering Corp. Shines in Positive Earnings Call
Premium
Company Announcements
Immuneering Corp. Shines in Positive Earnings Call
5M ago
IMRX
Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
Premium
Ratings
Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
6M ago
IMRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >